MOMETASONE FUROATE 0.1%w/w IP + SALICYLIC ACID 5.0%w/w IP

A topical corticosteroids and keratolytics are both used widely in the management of various dermatoses. (Laila Achampat, 2010) Promotes stratum corneum desquamation by dissolution of intercellular cement material. (Laila Achampat, 2010) Softens the scaly layers of psoriatic plaques and enhances the shedding of the stratum corneum. (John Koo MD, 1998) Salicylic acid enhances the anti-inflammatory effects of mometasone by facilitating the penetration into the stratum corneum. (Laila Achampat, 2010) A well-tolerated agent that has a rapid onset of action and relieves the symptoms of a flare-up by reducing inflammation, itching and redness. (Laila Achampat, 2010) A valuable therapeutic option for psoriasis due to its potent anti-inflammatory, and anti-pruritic properties. (Fabrizio Spada, 2018) A promising drug for patients with a variety of inflammatory skin conditions including psoriasis, eczema, atopic dermatitis and seborrheic dermatitis. (Fabrizio Spada, 2018) Displays statistically significant suppression of wheal as compared to mometasone 0.1% alone. (Laila Achampat, 2010) Significantly more efficacious than fluocinonide 0.05% ointment in the management of patients with plaque psoriasis. (R S Medansky, 1997) A safe and well-tolerated that provides more effective treatment of moderate-to-severe psoriasis than does mometasone furoate ointment alone. (J Koo, 1998)